Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) TA1144 8 April 2026 8 April 2026 ...

A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

Around 200 people with chronic lymphocytic leukaemia (CLL) whose disease has returned after treatment are set to benefit from a new treatment option. Our draft guidance recommends pirtobrutinib (also ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

Recommended medicines for weight management and related NICE guidance are shown in table 1. This should be read alongside NHS England's interim commissioning guidance for TA1026. All medicines for ...

This guidance has been updated and replaced by NICE technology appraisal guidance 946 ...

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...

Fezolinetant (also called Veoza and made by Astellas Pharma) is recommended to treat moderate to severe symptoms in final draft NICE guidance. Hot flushes and night sweats can hugely affect daily life ...

This guidance has been updated and replaced by NICE technology appraisal guidance 736 ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...